Space Industry and Business News  
SPACE MEDICINE
China embarks on clinical trial for virus vaccine
by Staff Writers
Beijing (AFP) March 22, 2020

Russia sends virus experts, medics to Italy
Moscow (AFP) March 22, 2020 - Russia on Sunday sent the first of nine military planes which are to take a total of 100 army virus experts and medics to Italy to help fight the coronavirus pandemic there.

The Russian defence ministry said the aid mission was agreed by President Vladimir Putin and Italian Prime Minister Giuseppe Conte.

They spoke on the phone Saturday evening, the Kremlin said.

The military transport planes arrived overnight at an aerodrome outside Moscow and eight medical teams were ready to fly out with mobile aerosol disinfecting units and medical equipment, the defence ministry said.

The first plane took off Sunday and was due to land at the Pratica di Mare military airport outside Rome, the ministry said.

The planes are set to fly out a group of around 100 people including specialists on viruses and epidemics from the defence ministry who have "significant international experience of fighting epidemics," it said.

The ministry said that the experts had previously taken part in fighting Ebola, African swine fever and anthrax outbreaks.

Russia has a total of 306 confirmed cases of coronavirus so far. Italy's death toll reached 4,825 on Saturday.

Putin visited Italy in July last year and has often spoken of his long friendship with former prime minister Silvio Berlusconi.

China has started the first phase of a clinical trial for a novel coronavirus vaccine, records show, as the world's scientists race to find a way to combat the deadly pathogen.

It comes after US health officials said last week they had started a trial to evaluate a possible vaccine in Seattle.

The Chinese effort began on March 16 -- the same day as the US announcement -- and is expected to continue until the end of the year, according to a filing in the country's Clinical Trial Registry, dated March 17.

"Volunteers of the COVID-19 phase one trial have already started receiving the vaccine," a staff member involved in the government-funded project told AFP on Sunday.

The 108 participants, aged between 18 and 60, will be tested in three groups and given different dosages. They are all residents of the central city of Wuhan -- where the new coronavirus first emerged late last year.

As the COVID-19 pandemic rages and governments step up protection measures, pharmaceutical companies and research labs around the world are working at full tilt.

There are currently no approved vaccines or medication for the new disease, which has killed more than 13,000 people worldwide so far.

The vaccine trial announcements come amid an escalating feud between the US and China over the pandemic, with President Donald Trump enraging Beijing by speaking of the "Chinese virus".

China's nationalistic Global Times published an opinion piece last week noting "the development of a vaccine is a battle that China cannot afford to lose".

But the quest is expected to take time -- the US candidate vaccine may take another year to 18 months before becoming available.

An antiviral treatment called remdesivir, made by US-based Gilead Sciences, is already in the final stages of clinical trials in Asia and doctors in China have reported it has proven effective in fighting the disease.

But only randomised trials will allow scientists to know for sure if it really helps or whether patients would have recovered without it.


Related Links
Space Medicine Technology and Systems


Thanks for being here;
We need your help. The SpaceDaily news network continues to grow but revenues have never been harder to maintain.

With the rise of Ad Blockers, and Facebook - our traditional revenue sources via quality network advertising continues to decline. And unlike so many other news sites, we don't have a paywall - with those annoying usernames and passwords.

Our news coverage takes time and effort to publish 365 days a year.

If you find our news sites informative and useful then please consider becoming a regular supporter or for now make a one off contribution.
SpaceDaily Contributor
$5 Billed Once


credit card or paypal
SpaceDaily Monthly Supporter
$5 Billed Monthly


paypal only


SPACE MEDICINE
Heat and light create new biocompatible microparticles
Durham NC (SPX) Mar 13, 2020
Biomedical engineers at Duke University have devised a method for making small particles that are safe for living tissues that will allow them to create new shapes attractive for drug delivery, diagnostics and tissue engineering. The results appear online on March 12 in the journal Nature Communications. "With nothing more than some heat and light, we can make some pretty bizarre microparticles," said Stefan Roberts, a biomedical engineering research scientist at Duke. "The technique is simp ... read more

Comment using your Disqus, Facebook, Google or Twitter login.



Share this article via these popular social media networks
del.icio.usdel.icio.us DiggDigg RedditReddit GoogleGoogle

SPACE MEDICINE
World Centric announces new World Centric leaf fiber lids

Creating custom light using 2D materials

Raytheon awarded $17 million for dual band radar spares for USS Ford

Time-resolved measurement in a memory device

SPACE MEDICINE
Northrop Grumman awarded $48.2M for MUOS satellite systems for Navy

Space and Missile Systems Center's multi-manifest satellite vehicle ready for integration on AEHF-6 mission

L3Harris nabs $383.2M to provide man pack radio systems for Marines

Lockheed Martin's Most Advanced Mobile Communications Satellite Launches

SPACE MEDICINE
SPACE MEDICINE
Chinese smartphone-maker debuts device with embedded ISRO navigation system

China launches new BeiDou navigation satellite

Beijing to beef up support for Beidou-related industry

Regulators move to fine telecoms for selling location data

SPACE MEDICINE
Wealthy flock to private jets as pandemic spreads and airlines tank

Optimised flight routes for climate-friendly air transport

Transportation Command head questions Air Force's plan for refueler upgrades

India, U.S. ink $3B deal for helicopters

SPACE MEDICINE
Semiconductors can behave like metals and even like superconductors

New error correction method provides key step toward quantum computing

The ink of the future in printed electronics

A small step for atoms, a giant leap for microelectronics

SPACE MEDICINE
More reliable rainfall forecasts for South Asian summer monsoons in coming decades

China's polar-observing satellite completes Antarctic mission

Observing animal migration from space - ISS experiment ICARUS begins

Kleos Data to Target Environmental Challenges in Brazil

SPACE MEDICINE
Study suggests LEGO bricks could survive in ocean for up to 1,300 years

Micro-pollution ravaging China and South Asia: study

Toxic mineral selenium to blame for spinal deformities in California Delta fish

First-time direct proof of chemical reactions in particulates









The content herein, unless otherwise known to be public domain, are Copyright 1995-2024 - Space Media Network. All websites are published in Australia and are solely subject to Australian law and governed by Fair Use principals for news reporting and research purposes. AFP, UPI and IANS news wire stories are copyright Agence France-Presse, United Press International and Indo-Asia News Service. ESA news reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. All articles labeled "by Staff Writers" include reports supplied to Space Media Network by industry news wires, PR agencies, corporate press officers and the like. Such articles are individually curated and edited by Space Media Network staff on the basis of the report's information value to our industry and professional readership. Advertising does not imply endorsement, agreement or approval of any opinions, statements or information provided by Space Media Network on any Web page published or hosted by Space Media Network. General Data Protection Regulation (GDPR) Statement Our advertisers use various cookies and the like to deliver the best ad banner available at one time. All network advertising suppliers have GDPR policies (Legitimate Interest) that conform with EU regulations for data collection. By using our websites you consent to cookie based advertising. If you do not agree with this then you must stop using the websites from May 25, 2018. Privacy Statement. Additional information can be found here at About Us.